

- 3 -

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

38. (Previously presented) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of glucagon-like peptide 1(7-36) amide analogue, wherein said glucagon-like peptide 1(7-36) amide analogue is administered subcutaneously.
39. (Previously presented) A method according to claim 38, wherein said mammal is a human.
40. (Previously presented) A method according to claim 39, wherein said insulin and said glucagon-like peptide 1(7-36) amide analogue are administered to the human at a selected time prior to ingestion of a meal.
41. (Previously presented) A method according to any of claims 38-40, wherein said glucagon-like peptide 1(7-36) amide analogue is a glucagon-like peptide 1(7-36).
42. (Previously presented) A method according to any of claims 38-41, wherein said glucagon-like peptide 1(7-36) amide analogue is glucagon-like peptide 1(7-37).
43. (Presently Amended) A method of treating insulin-requiring diabetes mellitus in a mammal, the method consisting essentially of comprising administering an effective amount of glucagon-like peptide 1(7-36) amide analogue wherein said glucagon-like peptide 1(7-36) amide analogue is administered subcutaneously.
44. (Previously presented) A method according to claim 43, wherein said mammal is a human.

- 4 -

45. (Previously presented) A method according to claim 44, wherein said glucagon-like peptide 1(7-36) amide analogue is administered to the human at a selected time prior to ingestion of a meal.

46. (Previously presented) A method according to any of claims 43-45, wherein said glucagon-like peptide 1(7-36) amide analogue is glucagon-like peptide 1(7-37).

47. (Previously presented) A method according to any of claims 43-45, wherein said glucagon-like peptide 1(7-36) amide analogue is glucagon-like peptide 1(7-36).

48. (Currently Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and a peptide selected from the group consisting of:

- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36) amide; and
- (c) an effective fragment or analogue of (a) or (b).

49. (Cancelled)

50. (Currently Amended) A method of treating insulin-requiring diabetes in a mammal comprising administering subcutaneously to the mammal an effective amount of a an insulin and glucagon-like peptide 1-related peptide.

51. (Cancelled)

52. (Currently Amended) The method according to any of claims 38, 43, 48 and 50, wherein the insulin-requiring diabetes is Type I diabetes.